Erratum:Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)
| Autor: | Hanzel, Jurij, Dreesen, Erwin, Vermeire, Severine, Löwenberg, Mark, Hoentjen, Frank, Bossuyt, Peter, Clasquin, Esme, Baert, Filip J., D'Haens, Geert R., Mathôt, Ron |
|---|---|
| Přispěvatelé: | Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Pharmacy, AII - Infectious diseases, Gastroenterology and hepatology |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Zdroj: | Hanzel, J, Dreesen, E, Vermeire, S, Löwenberg, M, Hoentjen, F, Bossuyt, P, Clasquin, E, Baert, F J, D'Haens, G R & Mathôt, R 2022, ' Erratum : Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143) ', Inflammatory Bowel Diseases, vol. 28, no. 5, pp. 817 . https://doi.org/10.1093/ibd/izab270 Inflammatory bowel diseases, 28(5). John Wiley and Sons Inc. Inflammatory Bowel Diseases, 28(5). John Wiley and Sons Inc. |
| ISSN: | 1078-0998 |
| DOI: | 10.1093/ibd/izab143) |
| Popis: | In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|